AZD2461: Novel PARP Inhibitor Advancing DNA Repair Research
2026-05-07
AZD2461, a potent and selective PARP inhibitor, transforms breast cancer research by overcoming Pgp-mediated resistance and enabling robust DNA repair pathway interrogation. Its unique properties and workflow flexibility empower researchers to model therapeutic responses and resistance mechanisms with new precision.
BMSC Exosomal Egr2 Regulates RNF8/DAPK1 Axis in Ischemic Str
2026-05-07
This study demonstrates that BMSC-derived exosomal Egr2 alleviates neuronal injury after ischemic stroke by modulating the RNF8/DAPK1 signaling axis. By integrating chromatin immunoprecipitation, co-immunoprecipitation, and functional assays, the authors clarify a novel mechanism for exosome-mediated neuroprotection with implications for targeted stroke therapies.
25-Hydroxycholesterol Shapes Immunosuppressive Macrophage Me
2026-05-06
Xiao et al. (2024) uncover how 25-hydroxycholesterol (25HC), produced via CH25H, accumulates in tumor-associated macrophages (TAMs) to drive immunosuppressive functions through AMPKa activation and metabolic reprogramming. Their findings highlight a metabolic checkpoint that can be therapeutically targeted to enhance anti-tumor immunity.
DMH1: Advanced ALK2 Inhibitor Protocols for Organoid & NSCLC
2026-05-06
DMH1, a potent ALK2 inhibitor from APExBIO, empowers researchers to precisely modulate BMP signaling in organoid and non-small cell lung cancer models. This guide translates recent reference breakthroughs into actionable workflows, troubleshooting strategies, and application-specific tips to maximize experimental reproducibility and biological insight.
Self-Assembling Virus-Mimicking Particles for Extrahepatic m
2026-05-05
The reference study introduces a modular, self-assembling enveloped virus-mimicking particle (EVMP) system to efficiently deliver mRNA to extrahepatic organs, overcoming the hepatic tropism of current platforms. This innovation enables precise, biosafe delivery of cytokine mRNAs, such as IL-12, broadening the scope of mRNA-based immunotherapy and gene expression studies.
Imatinib Hydrochloride: Applied Workflows for Kinase Inhibit
2026-05-05
Imatinib hydrochloride (STI571 hydrochloride) stands out as a multi-target tyrosine kinase inhibitor for cancer research, enabling precise modulation of v-Abl, c-Kit, and PDGFR-driven pathways. This guide translates the latest mechanistic insights and workflow optimizations into actionable protocols, empowering researchers to achieve reproducible, quantitative results in chronic myelogenous leukemia and gastrointestinal stromal tumor studies.
L-Glutathione Reduced: Optimizing Redox Control in Cancer Re
2026-05-04
L-Glutathione Reduced (APExBIO SKU B7775) empowers high-fidelity studies of cellular redox balance in contexts ranging from oxidative stress to targeted cancer metabolism research. This article delivers actionable protocol enhancements, troubleshooting tips, and translational insights, guided by recent GOT1 inhibition breakthroughs and validated by evidence-based workflows.
CDK4/6 and BET Inhibition Synergize to Suppress Pancreatic C
2026-05-04
Gu et al. demonstrate that dual inhibition of CDK4/6 and BET proteins markedly suppresses pancreatic tumor growth and reverses epithelial-to-mesenchymal transition (EMT) by modulating GSK3β-mediated Wnt/β-catenin signaling. This work provides mechanistic insight and preclinical evidence supporting combined targeted strategies for pancreatic ductal adenocarcinoma.
Impact of Antiarrhythmics on Cardiac SK Channels: New Insigh
2026-05-03
This study rigorously evaluated whether clinically used antiarrhythmic agents, including dronedarone (Multaq), modulate small conductance calcium-activated potassium (KCa2.X/SK) channels in human atrial cells. The findings clarify that most conventional antiarrhythmics, dronedarone included, do not significantly inhibit SK channels at therapeutic concentrations, thus informing ongoing research into atrial-selective targets for safer atrial fibrillation treatment.
PK/PD Targets for Gamithromycin Against S. suis in Piglets:
2026-05-02
This study defines pharmacodynamic targets and PK/PD cutoffs for gamithromycin against Streptococcus suis in piglets, providing a foundation for dose optimization in veterinary care. Findings highlight the importance of integrating serum matrix effects and MIC distributions to inform antibiotic stewardship and resistance management.
Mechanistic Innovation in mRNA Delivery: Dual Fluorescence S
2026-05-02
This thought-leadership article unpacks the mechanistic innovations embodied by EZ Cap™ Cy5 EGFP mRNA (5-moUTP) and offers translational researchers strategic guidance on optimizing non-viral mRNA delivery and functional readouts. By situating this product within the context of advanced electroporation technologies and emerging immune-evasive design, we provide actionable protocols, competitive benchmarks, and a visionary outlook on the future of gene regulation and cell therapy research.
Comparative Cardiovascular Outcomes of SGLT2 Inhibitors in T
2026-05-01
This systematic review and network meta-analysis rigorously compares the cardiovascular efficacy of individual SGLT2 inhibitors, including Ertugliflozin (PF-04971729), in type 2 diabetes patients with heart failure. Its findings clarify differential impacts on heart failure hospitalization and composite cardiovascular endpoints, guiding more evidence-based selection of SGLT2 inhibitors for comorbid T2D and heart failure populations.
A-1331852: Applied Use of a Potent BCL-XL Inhibitor in Cance
2026-04-30
A-1331852 offers bench researchers a highly selective tool for disrupting BCL-XL–BIM complexes, enabling targeted apoptosis induction in BCL-XL–dependent cancer and senescent cells. This article details practical workflows, protocol refinements, and troubleshooting insights to maximize the impact of A-1331852 in apoptosis assays and translational cancer models.
Phenothiazines Enhance Macrophage Antibacterial Activity via
2026-04-30
This study uncovers how phenothiazine compounds, including promethazine hydrochloride, boost the antibacterial defenses of macrophages by promoting reactive oxygen species production and autophagy. The findings offer new mechanistic insights for host-directed antibacterial strategies, especially in the context of rising antibiotic resistance.
DNase I (RNase-free): Precision DNA Removal for RNA Workflow
2026-04-29
DNase I (RNase-free) empowers researchers to achieve uncompromised RNA purity, even in the most complex tumor microenvironment studies. Its cation-tunable specificity and robust activity enable seamless DNA removal for RNA extraction, RT-PCR, and in vitro transcription—minimizing contamination and maximizing experimental fidelity.
466 records 20/32 page Previous Next First page 上5页 1617181920 下5页 Last page